Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab for acute ST-elevation myocardial infarction
NL-OMON59447Phase 2Not yet recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jun 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of rituximab in acute ST-segment elevation myocardial infarction (STEMI) and myocardial infarction (MI) (3 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Left ventricular ejection fraction by CMR at 6 months. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
rituximab
03
Conditions
acute ST-segment elevation myocardial infarction (STEMI)myocardial infarction (MI)
Beyond the preview
Go deeper on NL-OMON59447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59447.